Drug Patents owned by Biocryst

1. Drug name - ORLADEYO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10329260 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(12 years from now)

US10125102 BIOCRYST Human plasma kallikrein inhibitors
Apr, 2035

(12 years from now)

US10662160 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(17 years from now)

CN106257976B BIOCRYST Human Plasma Kallikrein Inhibitors
Mar, 2035

(12 years from now)

CN106257976A BIOCRYST Human Plasma Kallikrein Inhibitor
Mar, 2035

(12 years from now)

EP3113772A4 BIOCRYST Human Plasma Kallikrein Inhibitors
Mar, 2035

(12 years from now)

EP3113772A1 BIOCRYST Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors
Mar, 2035

(12 years from now)

EP3113772B8 BIOCRYST Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors
Mar, 2035

(12 years from now)

EP3113772B1 BIOCRYST Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors
Mar, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10689346 BIOCRYST Human plasma kallikrein inhibitors Mar, 2035

(12 years from now)

US11230530 BIOCRYST Human plasma kallikrein inhibitors Mar, 2035

(12 years from now)

US11117867 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor Nov, 2039

(17 years from now)

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 110MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

2. Drug name - RAPIVAB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6562861 BIOCRYST Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
Dec, 2023

(1 year, 2 months from now)

CN1282316A BIOCRYST Substituted Cyclopentane And Cyclopentene Compound Useful As Neuraminidase Inhibitors
Jun, 2005

(17 years ago)

EP1040094B1 BIOCRYST Substituted Cyclopentane And Cyclopentene Compounds Useful As Neuraminidase Inhibitors
Dec, 2018

(3 years ago)

EP1040094B9 BIOCRYST Substituted Cyclopentane And Cyclopentene Compounds Useful As Neuraminidase Inhibitors
Dec, 2018

(3 years ago)

EP1040094A4 BIOCRYST Substituted Cyclopentane And Cyclopentene Compounds Useful As Neuraminidase Inhibitors
Dec, 2018

(3 years ago)

EP1040094A1 BIOCRYST Substituted Cyclopentane And Cyclopentene Compounds Useful As Neuraminidase Inhibitors
Dec, 2018

(3 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10391075 BIOCRYST Antiviral treatments Feb, 2027

(4 years from now)

US8778997 BIOCRYST Antiviral treatments May, 2027

(4 years from now)

Drugs and Companies using PERAMIVIR ingredient

Treatment: Treatment of acute uncomplicated influenza in patients 2 years and older; treatment of acute uncomplicated influenza in patients 6 months and older; Treatment of acute uncomplicated influenza in patients 2 years and older; treatment of acute uncomplicated influenza in adults; treatment of acute uncomplicated influenza in patients 6 months and older

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
200MG/20ML (10MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.